Study to Evaluate the Safety, Reactogenicity and Immunogenicity of a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix, vs Hib-MenC or Priorix Only, in Toddlers (13-14 m) Primed With 3 Doses of Hib (as Part of a DTPa -Containing Vaccine) and MenC-CRM197 Conjugate Vaccines.

Trial Profile

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix, vs Hib-MenC or Priorix Only, in Toddlers (13-14 m) Primed With 3 Doses of Hib (as Part of a DTPa -Containing Vaccine) and MenC-CRM197 Conjugate Vaccines.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; Measles mumps and rubella virus vaccine
  • Indications Haemophilus infections; Measles; Meningococcal group C infections; Mumps; Rubella
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Mar 2010 Results published in the Pediatric Infectious Disease Journal
    • 27 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top